Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147598 | 0.82 | MAPT (0.79) | TDP1MAPTMEN1KMT2AHTT | |
| SCHEMBL8901888 | 0.76 | ABCG2 (0.76) | ABCG2 | |
| Hydrochloric Acid SCHEMBL8899114 | 0.75 | ABCG2 (0.75) | ABCG2 | |
| SCHEMBL5409656 | 0.74 | SYK (0.59) | MAPTMEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL19129462 | 0.72 | ABCG2 (0.67) | MAPTSMN1; SMN2LMNAABCG2 | |
| SCHEMBL4544763 | 0.72 | KCNH3 (0.67) | MAPTMEN1KMT2AHTTMAPK1 | |
| SCHEMBL4544822 | 0.72 | KCNH3 (0.67) | MAPTMEN1KMT2AHTTMAPK1 | |
| SCHEMBL6797660 | 0.72 | JAK2 (0.62) | MAPTMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL4544861 | 0.72 | KCNH3 (0.70) | MAPTMEN1KMT2AHTTMAPK1 | |
| SCHEMBL4544834 | 0.72 | KCNH3 (0.70) | MAPTMEN1KMT2AHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771331-B2 | Methods of identifying neuroprotective compounds for retinal ganglion cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | NLN, GAP43, AIFM1 | TDP1 1283/4885MAPT 561/4885MEN1 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.